inVentiv closes i3 deal
13 June 2011 | Jonathan Hare Scrip Clinical Research
Interview: Mundipharma's emerging markets architect on growth in China and opioid regs Interview: Dr Reddy's CEO on move from curing diseases to managing health BioNotebook: Blend raises VC cash; Actavis gets quick Namenda appeal; and three new deals Fudged ECG reports: GVK blunder or overblown storm?
Other Features & Analysis
Breaking through the sales plateau in 3 stages Expert view: Navigating the changing landscape of transfer pricing Conducting drug clinical trials in Russia: today and what lies ahead US regulations for drugs and devices - the shape of things to come